Refractory Diabetic Macular Edema
Conditions
Brief summary
after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened . Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years . How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches. In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.
Interventions
DRUGinjection of bevacizumab and erythropoietin
injection of bevacizumab and erythropoietin
DRUGinjection of bevacizumab
under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
Sponsors
Shahid Beheshti University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Patient with refractory diabetic macular edema at least one month after third injection
Exclusion criteria
* previous vitreoretinal surgery previous glaucoma surgery glaucomatous patient open heart surgery active proliferative diabetic retinopathy one eye patients vitreous hemorrhage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| best corrected visual acuity | 1 month | Snellen chart |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Optical coherence tomography | 1 month | Optical coherence tomography |
Countries
Iran
Contacts
Primary ContactMorteza Entezari, MD
Outcome results
None listed